Y Intercept Hong Kong Ltd Has $10.03 Million Position in Encompass Health Corporation $EHC

Y Intercept Hong Kong Ltd lifted its stake in Encompass Health Corporation (NYSE:EHC) by 1,249.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 94,462 shares of the company’s stock after purchasing an additional 87,460 shares during the period. Y Intercept Hong Kong Ltd’s holdings in Encompass Health were worth $10,026,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of EHC. Northwestern Mutual Wealth Management Co. increased its holdings in shares of Encompass Health by 3,059,159.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock valued at $402,640,000 after purchasing an additional 3,793,358 shares in the last quarter. Norges Bank acquired a new stake in shares of Encompass Health in the fourth quarter valued at approximately $133,221,000. Millennium Management LLC boosted its stake in Encompass Health by 140.0% in the third quarter. Millennium Management LLC now owns 1,223,665 shares of the company’s stock valued at $155,430,000 after acquiring an additional 713,738 shares during the last quarter. 8 Knots Management LLC bought a new position in Encompass Health in the second quarter valued at approximately $78,644,000. Finally, Alliancebernstein L.P. boosted its stake in Encompass Health by 23.4% in the third quarter. Alliancebernstein L.P. now owns 2,515,878 shares of the company’s stock valued at $319,567,000 after acquiring an additional 476,564 shares during the last quarter. Institutional investors and hedge funds own 97.25% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on EHC. Wall Street Zen raised shares of Encompass Health from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. TD Cowen began coverage on shares of Encompass Health in a research note on Thursday, May 28th. They issued a “buy” rating and a $125.00 price objective on the stock. Barclays reduced their price objective on shares of Encompass Health from $153.00 to $140.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 5th. Leerink Partners set a $152.00 price objective on shares of Encompass Health in a research note on Friday, May 22nd. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Encompass Health in a research note on Monday. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $143.86.

Insider Buying and Selling at Encompass Health

In other news, EVP Patrick William Tuer sold 682 shares of Encompass Health stock in a transaction on Monday, May 11th. The shares were sold at an average price of $104.56, for a total transaction of $71,309.92. Following the transaction, the executive vice president directly owned 24,755 shares of the company’s stock, valued at $2,588,382.80. This trade represents a 2.68% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.80% of the stock is currently owned by corporate insiders.

Encompass Health Trading Down 0.9%

Shares of NYSE EHC opened at $101.49 on Friday. The company’s fifty day moving average is $104.31 and its 200-day moving average is $104.65. The stock has a market cap of $10.07 billion, a price-to-earnings ratio of 16.94, a P/E/G ratio of 2.23 and a beta of 0.72. Encompass Health Corporation has a twelve month low of $92.77 and a twelve month high of $127.99. The company has a quick ratio of 1.17, a current ratio of 1.17 and a debt-to-equity ratio of 0.76.

Encompass Health (NYSE:EHC) last announced its quarterly earnings results on Thursday, April 30th. The company reported $1.60 earnings per share for the quarter, topping analysts’ consensus estimates of $1.51 by $0.09. The company had revenue of $1.59 billion for the quarter, compared to analysts’ expectations of $1.57 billion. Encompass Health had a net margin of 10.04% and a return on equity of 18.28%. The business’s quarterly revenue was up 9.0% compared to the same quarter last year. During the same period last year, the firm posted $1.37 earnings per share. Encompass Health has set its FY 2026 guidance at 5.890-6.110 EPS. Equities research analysts predict that Encompass Health Corporation will post 5.97 EPS for the current year.

Encompass Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Wednesday, July 1st will be given a dividend of $0.19 per share. This represents a $0.76 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date of this dividend is Wednesday, July 1st. Encompass Health’s dividend payout ratio (DPR) is currently 12.69%.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.